| pubmed-article:18729190 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C0546837 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C1704858 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C2825965 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C0536940 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C0301872 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C1413787 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C0205276 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C0205100 | lld:lifeskim |
| pubmed-article:18729190 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:18729190 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:18729190 | pubmed:dateCreated | 2008-9-22 | lld:pubmed |
| pubmed-article:18729190 | pubmed:abstractText | NY-ESO-1 antigen is a prototype of a class of cancer/testis antigens. We carried out a clinical trial using NY-ESO-1 whole protein as a cancer vaccine for 13 advanced cancer patients. We have recently reported that vaccine elicited humoral and cellular immune responses in 9 cancer patients including 4 esophageal cancer patients, and clinical responses were also observed in 4 of 5 evaluable patients. In this study, we analyzed the responses in 8 esophageal cancer patients including 4 newly enrolled patients. Patients were injected subcutaneously at biweekly intervals with NY-ESO-1 recombinant protein formulated with cholesterol-bearing hydrophobized pullulan. Induction of antibody, and CD4 and CD8 T-cell responses were observed in 7, 7 and 6 patients, respectively, out of 8 patients. 1 PR, 2 SD and 2 mixed clinical responses were observed in 6 evaluable patients. No significant adverse events were observed. Furthermore, we analyzed NY-ESO-1 and MHC class I expression and the infiltration of immune cells into tumor samples obtained before and after vaccination from 4 patients by immunohistochemistry. The results showed 2 patients with disappearance of CD4 and CD8 T-cell infiltration, 1 patient with increase in the number of CD68(+) macrophages and 1 patient with tumor antigen loss in the progressive tumors following vaccinations. The induction of NY-ESO-1 immunity and some preferable clinical outcomes were observed in esophageal cancer patients by vaccination with NY-ESO-1. However, the tumors grew eventually by various mechanisms after vaccination. | lld:pubmed |
| pubmed-article:18729190 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18729190 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18729190 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18729190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18729190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18729190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18729190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18729190 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18729190 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:18729190 | pubmed:issn | 1097-0215 | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:MondenMoritoM | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:MiyataHiroshi... | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:ShikuHiroshiH | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:JungbluthAchi... | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:DokiYuichiroY | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:UenakaAkikoA | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:NakayamaEiich... | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:OldLloyd JLJ | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:RitterGerdG | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:SatoEiichiE | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:HoffmanEric... | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:KawabataRyohe... | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:MurphyRogerR | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:WadaHisashiH | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:YamasakiMakot... | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:IwaeShigemich... | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:YonezawaKouic... | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:IsobeMidoriM | lld:pubmed |
| pubmed-article:18729190 | pubmed:author | pubmed-author:NakamuraYurik... | lld:pubmed |
| pubmed-article:18729190 | pubmed:copyrightInfo | (c) 2008 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:18729190 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18729190 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18729190 | pubmed:volume | 123 | lld:pubmed |
| pubmed-article:18729190 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18729190 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18729190 | pubmed:pagination | 2362-9 | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:meshHeading | pubmed-meshheading:18729190... | lld:pubmed |
| pubmed-article:18729190 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18729190 | pubmed:articleTitle | Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. | lld:pubmed |
| pubmed-article:18729190 | pubmed:affiliation | Department of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. hwada@gesurg.med.osaka-u.ac.jp | lld:pubmed |
| pubmed-article:18729190 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18729190 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18729190 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18729190 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18729190 | lld:pubmed |
